A note on this column: This article is general medical information, not a description of a service offered at this practice. Dr. Ishiguro's surgical practice is focused on hip and knee conditions — he does not treat Dupuytren's contracture or other hand and wrist disorders. This column is written to help readers understand a common condition and know when and how to seek the right specialist, typically a hand surgeon (orthopaedic or plastic surgery trained) or a hand therapist.
What Dupuytren's contracture actually is
Dupuytren's contracture — also called Dupuytren's disease — is a slowly progressive thickening and contraction of the palmar fascia, the thin sheet of connective tissue that lies just beneath the skin of the palm and helps anchor the skin during grip. In the disease process, cells within this fascia (myofibroblasts) proliferate and lay down excess collagen, forming firm nodules and, over time, thick cords that run from the palm into one or more fingers.
As a cord matures, it gradually loses the ability to stretch, pulling the affected finger — most often the ring or little finger — into a fixed, bent position at the knuckle and middle joints. The process is typically painless and progresses over months to years, which is part of why many people delay seeking evaluation: an early nodule can look and feel like nothing more than a callus.
Who gets it, and why
Dupuytren's contracture is common: population-based estimates put overall prevalence at roughly 7–8%, with men affected three to four times more often than women, and incidence rising sharply with age, particularly after 50. The exact cause is not fully understood, but the disease clusters strongly in families and has a genetic component that twin studies have estimated at around 80% heritability — among the highest of any common musculoskeletal condition.
Recognised risk factors
- Northern European ancestry — historically the most strongly associated ethnic background, though the condition occurs in all populations
- Family history — first-degree relatives of an affected person have a substantially higher lifetime risk
- Male sex and age over 50 — the single strongest demographic pattern
- Smoking and alcohol use — both consistently associated with higher risk in population studies
- Diabetes mellitus — associated with a distinct pattern, often affecting the middle finger and following a milder course
- Manual labour and repetitive hand vibration or microtrauma — a debated but recognised contributing factor, sometimes discussed in the context of work-related injury claims
- Epilepsy and certain anticonvulsant medications — an association reported in several case series
What the evidence shows: A 2024 review in Die Orthopädie summarising the epidemiological literature reports an overall prevalence of 7–8%, with men affected three to four times more frequently than women, and identifies work-related microtrauma, nicotine and alcohol use, epilepsy, and diabetes mellitus, together with advancing age, as the main recognised risk factors; the disease itself is described as a fibroproliferative process with no medication currently able to halt its progression (Harbrecht, Honigmann & Löw, Die Orthopädie, 2024). Separately, a large Danish twin study of 30,330 twin pairs found a probandwise concordance of 37% in identical twins versus 7% in non-identical twins, from which the heritability of Dupuytren's disease was calculated at approximately 80% (Larsen et al., J Hand Surg Eur Vol, 2015). A genome-wide association study has since identified dozens of contributing genetic variants, many clustered around genes in the Wnt signalling pathway, which is known to regulate fibrosis (Ng et al., Am J Hum Genet, 2017).
How the diagnosis is made
Dupuytren's contracture is diagnosed clinically, almost always without any need for imaging. A hand surgeon or physician examines the palm for firm nodules and cords, checks which fingers and joints are involved, and measures how much active extension has been lost at the knuckle (metacarpophalangeal) and middle (proximal interphalangeal) joints.
A simple, well-known screening tool is the "tabletop test": the patient tries to lay the affected hand completely flat on a table. An inability to do so — because a finger sits raised off the surface — is a practical sign that the contracture has reached a point where treatment is worth discussing. Beyond the fingers, Dupuytren's disease can occasionally appear as isolated nodules elsewhere, such as the knuckles (Garrod's pads) or, less commonly, the soles of the feet or the penis (Ledderhose disease and Peyronie's disease, respectively), reflecting a shared underlying fibrotic tendency in some patients.
What the evidence says about treatment
There is no medical treatment that reverses or halts the underlying fibrotic process, so management is directed at correcting contracture once it interferes with function — grip, hand-washing, wearing gloves, or shaking hands are common triggers for seeking care. Early, mild nodules without contracture are generally simply observed.
Commonly used treatment options
- Observation — appropriate for nodules or minimal contracture that isn't yet affecting hand function
- Percutaneous needle aponeurotomy (fasciotomy) — a needle is used through the skin to divide the cord at multiple points without an open incision; minimally invasive with a fast recovery, but a higher chance the cord will reform over time
- Collagenase clostridium histolyticum injection — an enzyme injected directly into the cord to weaken it, followed by a manual manipulation to snap it a day or two later; also minimally invasive, done in clinic
- Limited fasciectomy — open surgical excision of the diseased fascia through an incision in the palm; more invasive and a longer recovery, but generally the most durable correction
- Dermofasciectomy with skin grafting — removal of both the diseased fascia and overlying skin, generally reserved for recurrent or aggressive disease
Because needle aponeurotomy and collagenase injection are both less invasive than surgery, they are often tried first for suitable cord patterns, particularly at the knuckle joint, where results tend to be best for all three approaches. Comparative trial data give a reasonably clear picture of the trade-offs between the three main options.
What the evidence shows: A 2025 systematic review and meta-analysis of 11 randomised controlled trials (969 patients) found no significant difference in successful contracture correction between collagenase injection and needle aponeurotomy (relative risk 1.01, 95% CI 0.93–1.09), and similar recurrence rates between the two (relative risk 1.18, 95% CI 0.95–1.48). However, collagenase injection carried a substantially higher risk of recurrence compared with limited fasciectomy (relative risk 6.84, 95% CI 1.59–29.48), and was also associated with more local complications such as bruising, pain, and swelling (Cevik et al., J Plast Surg Hand Surg, 2025).
What the evidence shows: A network meta-analysis of randomised trials comparing all three main techniques found that limited fasciectomy produced significantly less residual contracture (measured as total passive extension deficit) than either collagenase injection or needle aponeurotomy, both in the short term (1–12 weeks) and in the long term (beyond 2 years), and provided more durable correction overall — though at the cost of a more invasive procedure and longer recovery (Obed, Salim, Schlottmann et al., BMC Musculoskeletal Disorders, 2022).
| Approach | Invasiveness / recovery | Durability |
|---|---|---|
| Needle aponeurotomy | In-clinic, no incision; days to return to activity | Fast relief; comparatively higher recurrence over years |
| Collagenase injection | In-clinic, two visits; days to a week to recover | Similar short-term result to needling; recurrence higher than surgery |
| Limited fasciectomy | Operating room, incision, hand therapy; weeks of recovery | Most durable correction in long-term comparisons |
Recurrence — the reappearance of contracture in a previously treated finger — is common with all three approaches and is a defining feature of the disease rather than a sign that treatment failed outright. Rates vary considerably between studies depending on how recurrence is defined and how long patients are followed, which is one reason the choice between a quicker, less durable option and a more invasive, more durable one is often made jointly between patient and surgeon based on the patient's age, disease aggressiveness, joints involved, and personal priorities around downtime.
When to see a specialist
A firm nodule or cord in the palm that is not painful and not limiting hand use can reasonably be watched without urgency. Evaluation by a hand specialist is worthwhile once a finger cannot be laid flat on a tabletop, once fine motor tasks such as putting on gloves or reaching into a pocket become difficult, or once the middle joint of the finger (rather than just the knuckle) becomes involved, since contractures at this joint are generally harder to fully correct the longer they are left untreated.
References (PubMed / Journal)
Harbrecht A, Honigmann P, Löw S, et al. Morbus Dupuytren [Dupuytren's disease: Epidemiology, diagnosis, treatment, outcome]. Orthopädie (Heidelb). 2024;53(11):893–902. DOI: 10.1007/s00132-024-04553-z
Larsen S, Krogsgaard DG, Larsen LA, Iachina M, Skytthe A, Frederiksen H. Genetic and environmental influences in Dupuytren's disease: a study of 30,330 Danish twin pairs. J Hand Surg Eur Vol. 2015;40(2):171–176. DOI: 10.1177/1753193414535720
Ng M, Thakkar D, Southam L, et al. A Genome-wide Association Study of Dupuytren Disease Reveals 17 Additional Variants Implicated in Fibrosis. Am J Hum Genet. 2017;101(3):417–427. DOI: 10.1016/j.ajhg.2017.08.006
Cevik J, Rajaram R, Pollock M, Seth I, Rozen WM. Collagenase clostridium histolyticum for Dupuytren's disease: a comprehensive systematic review and comparative analysis against percutaneous needle aponeurotomy and limited fasciectomy. J Plast Surg Hand Surg. 2025;60:27–34. DOI: 10.2340/jphs.v60.42750
Obed D, Salim M, Schlottmann F, et al. Short-term efficacy and adverse effects of collagenase clostridium histolyticum injections, percutaneous needle fasciotomy and limited fasciectomy in the treatment of Dupuytren's contracture: a network meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2022;23:945. DOI: 10.1186/s12891-022-05894-6